Incyte and MorphoSys U.S. Inc.: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix)

Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary

Related Keywords

Boston ,Massachusetts ,United States ,Germany ,Florida ,Delaware ,Orlando ,Canada ,Planegg ,Bayern ,University Hospital ,American ,Steven Stein ,Johannes Duell ,Kaitlyn Nealy ,Julia Neugebauer ,Christine Chiou ,Thomas Biegi ,Jenifer Antonacci ,Tim Demuth ,Public Affairs ,Morphosys Us Inc ,American Association For Cancer Research ,Exchange Commission ,American Association For Cancer Research Annual Meeting ,Practice Research Clinical Haematology ,Linkedin ,Nasdaq ,Xencor Inc ,Drug Administration ,Twitter ,American Association ,Cancer Research Annual Meeting ,Cancer Research ,Annual Meeting ,Medical Clinic ,Chief Research ,Development Officer ,Chief Medical Officer ,Diffuse Largeb Cell Lymphoma ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Safety Information ,Medication Guide ,Prescribing Information ,Patient Information ,Important Safety ,Sys Forward Looking Statements ,Morphosy Annual Report ,Forward Looking Statements ,Practice Research Clinical ,Investor Relations ,Incyte ,Morphosys ,Nnounce ,Five ,Ear ,Results ,Wind ,Study ,Howed ,Bprolonged ,Durable ,Responses ,Relapsed ,Refractory ,Dlbcl ,Patients ,Reated ,Monjuvi ,Tafasitamab ,Wxix ,